Deterding Robin R
Department of Pediatrics, Pulmonary Medicine Section, University of Colorado, Denver, Colorado; and Breathing Institute, Children's Hospital Colorado, Aurora, Colorado.
Ann Am Thorac Soc. 2015 Oct;12(10):1451-7. doi: 10.1513/AnnalsATS.201508-558PS.
Children's interstitial and diffuse lung disease (chILD) is a term that encompasses a large and diverse group of rare pediatric diseases and disorders. Significant progress has been made over the last 2 decades in classification, clinical care, research, and organizational structure to enhance the care of children with these high-morbidity and -mortality diseases. New diseases have been defined clinically and genetically, classification systems developed and applied, organizations formed such as the chILD Research Network (chILDRN) and chILD Foundation, and basic and translational science expanded to focus on chILD diseases. Multidisciplinary collaborations and efforts to advance understanding and treatment of chILD have been extended worldwide. The future horizon holds great promise to expand scientific discoveries, collaborate more broadly, and bring new treatment to these children. An overview of key historical past developments, major clinical and research updates, and opportunities for the future in chILD is reviewed in this Perspective.
儿童间质性和弥漫性肺病（chILD）是一个涵盖大量且多样的罕见儿科疾病和病症的术语。在过去20年里，在分类、临床护理、研究和组织结构方面取得了重大进展，以加强对这些高发病率和高死亡率疾病患儿的护理。临床上和基因层面定义了新的疾病，开发并应用了分类系统，成立了诸如儿童间质性肺病研究网络（chILDRN）和儿童间质性肺病基金会等组织，基础科学和转化科学也得到扩展，专注于儿童间质性肺病相关疾病。推进对儿童间质性肺病的理解和治疗的多学科合作与努力已扩展至全球。未来前景有望扩大科学发现、更广泛地开展合作，并为这些儿童带来新的治疗方法。本观点文章综述了儿童间质性肺病关键的历史发展、主要的临床和研究进展以及未来的机遇。
